There are 2949 resources available
626P - Cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice: Interim analysis of the non-interventional SCOPE study
Presenter: Carsten Bokemeyer
Session: E-Poster Display
Resources:
Abstract
627P - Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD
Presenter: Ronald de Wit
Session: E-Poster Display
Resources:
Abstract
628P - Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
Presenter: Casilda Llacer Perez
Session: E-Poster Display
Resources:
Abstract
629P - Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
Presenter: Ronald de Wit
Session: E-Poster Display
Resources:
Abstract
630P - Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study
Presenter: Heather Payne
Session: E-Poster Display
Resources:
Abstract
631P - Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)
Presenter: Daniel George
Session: E-Poster Display
Resources:
Abstract
632P - Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)
Presenter: Stephane Oudard
Session: E-Poster Display
Resources:
Abstract
633P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Karim Fizazi
Session: E-Poster Display
Resources:
Abstract
634P - Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison” of the STAMPEDE trial
Presenter: Aine Haran
Session: E-Poster Display
Resources:
Abstract
635P - ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Presenter: Antonio Alcaraz
Session: E-Poster Display
Resources:
Abstract